The interdisciplinary „Swiss Task Force for Cannabinoids in Medicine“ (STCM) was founded in 2009. Members of the STCM are clinicians, pharmacists, lawyers and other professionals, who are – either in the doctor‘s office, university research lab, public pharmacy or law office -
Switzerland pursues a progressive drug policy and plays an international pioneering role, such as regarding the 4-
Consequently, the STCM aims at presenting current scientific, health political, legal and regulatory facts as base for an objective pro and cons discussion of the remedicinalisation of cannabinoids and cannabis products. The STCM addresses to medical professionals, scientists, caregivers, patients, patient organisations, politicians, regulatory authorities, and media people.
Since 2016 the STCM is the Swiss Ambassador of the international partner organization IACM.